These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12630232)

  • 21. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
    Demko S; Summers J; Keegan P; Pazdur R
    Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical presentation of varicella zoster in a patient on alemtuzumab.
    Venkatachalapathy S; Crowe J; Gray A
    Br J Haematol; 2007 Aug; 138(4):406. PubMed ID: 17659051
    [No Abstract]   [Full Text] [Related]  

  • 24. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
    Bauduer F
    Presse Med; 2009 Jan; 38(1):140-2. PubMed ID: 19004611
    [No Abstract]   [Full Text] [Related]  

  • 27. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
    Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taking the measure of alemtuzumab.
    Gilleece MH
    Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
    [No Abstract]   [Full Text] [Related]  

  • 29. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
    Saadeh CE; Srkalovic G
    Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P; Skotnicki AB; Robak T; Jaksic B; Dmoszynska A; Wu J; Sirard C; Mayer J
    J Clin Oncol; 2007 Dec; 25(35):5616-23. PubMed ID: 17984186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
    Zent CS; Kay NE
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):107-13. PubMed ID: 16163170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 33. Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?
    Oberoi SS; Abou Jawde RM
    J Clin Oncol; 2008 Dec; 26(35):5827-8; author reply 5828-9. PubMed ID: 19001335
    [No Abstract]   [Full Text] [Related]  

  • 34. Leukocyte depletion for leukaemia and multiple sclerosis.
    Bonn D
    Mol Med Today; 1998 Dec; 4(12):508. PubMed ID: 9866817
    [No Abstract]   [Full Text] [Related]  

  • 35. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 36. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
    Anoop P; Wotherspoon A; Matutes E
    Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
    [No Abstract]   [Full Text] [Related]  

  • 38. Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
    Sirard C; Trehu EG
    J Clin Oncol; 2008 May; 26(14):2411-2; author reply 2412-3. PubMed ID: 18467736
    [No Abstract]   [Full Text] [Related]  

  • 39. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia.
    Laurenti L; Piccioni P; Tarnani M; Chiusolo P; Piccirillo N; Rumi C; Sora F; Sica S; Leone G
    Leukemia; 2005 Jan; 19(1):153-4. PubMed ID: 15496971
    [No Abstract]   [Full Text] [Related]  

  • 40. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.